A Phase 2 interventional study of Voclosporin Ophthalmic Solution and Restasis® in Dry Eye, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-08.
Sponsored by Aurinia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 183rd largest by enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2018, is one of 97 in phase 2, and was the 266th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Ages 18+
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eye Research Associates, LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
544 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 36 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 473 interventional studies, 80 across the 64 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
330 of 544 have an industry lead sponsor. The 10 most frequent:
Aurinia Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Aurinia Pharmaceuticals Inc. has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
31 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 544 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).
This is a Phase 2, multi-center, Investigator-masked, randomized, parallel-group study to evaluate the tolerability, efficacy and safety of VOS versus Restasis® over a 28-day treatment period in subjects with mild to moderate DED. Approximately 90 subjects will be randomized to either VOS or Restasis® at approximately 7 centers located in the US
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have ongoing DED, as defined by at least one eye (if one eye, the same eye) meeting all the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.2% VOS, Twice Daily (BID), both eyes for 28 days
Drug: Voclosporin Ophthalmic Solution
0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days
Drug: Restasis®
Investigational Drug
Also known as: 0.2% VOS
Comparator
Also known as: RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%
Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1
Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".
Time frame: 1-minute Post Dose 1 installation (Day 1)
Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28
Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".
Time frame: Day 28
Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28
Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no burning/stinging" and 100 corresponds to "worst burning/stinging".
Time frame: Day 28
Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28
Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no foreign body sensation" and 100 corresponds to "worst foreign body sensation".
Time frame: 28 days
Change From Baseline in Photophobia Post Dose Instillation on Day 28
Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no photophobia" and 100 corresponds to "worst photophobia".
Time frame: 28 days
Change From Baseline in Eye Pain Post Dose Instillation on Day 28
Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye pain" and 100 corresponds to "worst eye pain".
Time frame: 28 days
Change From Baseline in Eye Dryness Post Dose Instillation on Day 28
Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye dryness" and 100 corresponds to "worst eye dryness".
Time frame: 28 days
Change From Baseline in Itching Post Dose Instillation on Day 28
Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no itching" and 100 corresponds to "worst itching".
Time frame: 28 days
Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores
The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms).
Time frame: Day 28
Change From Baseline in Symptom Assessment in Dry Eye Score (SANDE)
The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = "rarely" and 100mm = "all the time". For Severity of Symptoms 0mm = "very mild" and 100mm = "very severe". Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an "X" on the relevant horizontal line. The length of the line between the "rarely" or "very mild" starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters.
Time frame: Day 28
Change From Baseline in Unanesthetized Schirmer Test Score
The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is ≥10mm of wetting on the test strip, and severe dry eye is \<5mm of wetting on the test strip.
Time frame: 28 days
Change From Baseline in Fluorescein Corneal Staining (FCS) Score
The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome.
Time frame: 28 days
Recruitment period from August 2018 - December 2018
| Milestone | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Started | 51 | 49 |
| Completed | 47 | 49 |
| Not completed | 4 | 0 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Protocol non-compliance | 1 | 0 |
Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1 | 7.9 ± 17.95 | 3.5 ± 13.30 |
Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no discomfort" and 100 corresponds to "maximal discomfort".
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28 | 11.8 ± 20.64 | 6.1 ± 17.79 |
Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no burning/stinging" and 100 corresponds to "worst burning/stinging".
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28 | -12.3 ± 33.22 | -20.1 ± 25.11 |
Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no foreign body sensation" and 100 corresponds to "worst foreign body sensation".
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28 | -19.7 ± 35.8 | -20.7 ± 32.95 |
Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no photophobia" and 100 corresponds to "worst photophobia".
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Change From Baseline in Photophobia Post Dose Instillation on Day 28 | -23.1 ± 26.35 | -26.2 ± 25.91 |
Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye pain" and 100 corresponds to "worst eye pain".
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Change From Baseline in Eye Pain Post Dose Instillation on Day 28 | -13.9 ± 31.39 | -19.9 ± 28.62 |
Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no eye dryness" and 100 corresponds to "worst eye dryness".
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Change From Baseline in Eye Dryness Post Dose Instillation on Day 28 | -35.0 ± 27.59 | -34.6 ± 27.73 |
Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to "no itching" and 100 corresponds to "worst itching".
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Change From Baseline in Itching Post Dose Instillation on Day 28 | -26.9 ± 27.41 | -28.1 ± 30.88 |
The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms).
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores | -130.9 ± 144.95 | -149.6 ± 126.16 |
The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = "rarely" and 100mm = "all the time". For Severity of Symptoms 0mm = "very mild" and 100mm = "very severe". Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an "X" on the relevant horizontal line. The length of the line between the "rarely" or "very mild" starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters.
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Frequency | -28.0 ± 29.37 | -37.9 ± 27.24 |
| Severity | -24.9 ± 34.06 | -36.1 ± 24.84 |
The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is ≥10mm of wetting on the test strip, and severe dry eye is \<5mm of wetting on the test strip.
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Left Eye | 8.5 ± 10.52 | 3.0 ± 9.03 |
| Right Eye | 8.2 ± 10.64 | 3.3 ± 8.39 |
The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome.
| mm | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Left Eye | -2.2 ± 2.90 | -0.2 ± 3.05 |
| Right Eye | -2.2 ± 3.15 | -0.7 ± 2.79 |
Collected over 28 days +/- 3 days (follow-up period). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voclosporin Ophthalmic Solution (VOS) | 0/51 (0%) | 0/51 (0%) | 10/51 (19.6%) |
| Comparator | 0/49 (0%) | 0/49 (0%) | 6/49 (12.2%) |
| Event | Voclosporin Ophthalmic Solution (VOS) | Comparator |
|---|---|---|
| Ocular DiscomfortEye disorders | 7/51 | 5/49 |
| Instillation site painGeneral disorders | 3/51 | 1/49 |
| Lacrimation increasedEye disorders | 0/51 | 2/49 |
| Age, Continuous(years) | Voclosporin Ophthalmic Solution (VOS) | Comparator | Total |
|---|---|---|---|
| Mean | 57.5 ± 14.51 | 60.2 ± 15.08 | 58.9 ± 14.78 |
| Sex: Female, Male(Participants) | Voclosporin Ophthalmic Solution (VOS) | Comparator | Total |
|---|---|---|---|
| Female | 42 | 38 | 80 |
| Male | 9 | 11 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Voclosporin Ophthalmic Solution (VOS) | Comparator | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 10 | 23 |
| Not Hispanic or Latino | 38 | 39 | 77 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Voclosporin Ophthalmic Solution (VOS) | Comparator | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 8 | 21 |
| White | 35 | 36 | 71 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Duration of Dry Eye Disease(years) | Voclosporin Ophthalmic Solution (VOS) | Comparator | Total |
|---|---|---|---|
| Median | 2.85 (1.62 to 6.13) | 2.67 (1.25 to 6.27) | 2.85 (1.45 to 6.14) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Nov 2018, 2 months.
Results were first posted in Jul 2021, 2 years 7 months after primary completion. A results delay was requested in Jan 2019.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 2 months is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Aurinia Pharmaceuticals Inc.